Polaris Group (TPE:6550) completed its rolling biologic license application submission to the US Food and Drug Administration for a drug to treat rare lung cancer called malignant pleural mesothelioma.

The drug is named ADI-PEG 20, and is also known as Pegargiminase, according to a Tuesday Taiwan Exchange filing.

The FDA is expected to respond within 60 days, as the drug holds orphan designation, the company said.

Polaris shares jumped nearly 10% in afternoon trade Wednesday.